Emcure board to consider Q2 FY26 results on Nov 3

Results View source PDF Explain this filing

EMCURE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.3%Reaction day

₹1860.00

prior close

₹1860.00

announcement price

After-mkt

timing

Nifty Smallcap 250market-1.2%-0.1% vs market

Pharmaceuticals peers, median of 172sector-0.6%-0.7% vs sector

On the reaction day the stock moved 0.1 pts less than Nifty Smallcap 250 and 0.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.9

10m

+0.4

15m

+0.0

30m

+0.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.3-1.2-0.1-0.6-0.7

Next day

-2.0-1.1-1.0-0.7-1.4

-4.9-2.2-2.7-1.9-3.0

-5.5-4.4-1.1-3.5-2.0

-4.3-5.5+1.2-4.4+0.1

-4.5-8.1+3.6-6.1+1.5

+0.3pendingpending-2.9+3.2

15d

—————

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 172Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Emcure Pharmaceuticals has informed exchanges that its Board of Directors will meet on November 3, 2026 to consider and approve the Unaudited Financial Results (both Standalone and Consolidated) for the quarter and half-year ended September 30, 2026. The trading window for designated persons is already closed from October 1, 2026 and will remain closed till November 5, 2026, i.e. 48 hours after results are declared.

Likely market impact

Routine pre-results intimation. Watch for the Q2 and H1 FY26 numbers on Nov 3 for revenue and profit trends.